Research programme: MOR 101 antibodies - MorphoSys

Drug Profile

Research programme: MOR 101 antibodies - MorphoSys

Alternative Names: MOR 101 antibodies (Fab fragment); MOR 101 antibodies research programme - MorphoSys; MOR101

Latest Information Update: 16 Mar 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MorphoSys
  • Class
  • Mechanism of Action Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Burns

Most Recent Events

  • 24 Feb 2006 Discontinued - Preclinical for Burns in Germany (unspecified route)
  • 16 May 2005 This programme is still in active development - (BioSquare-2005)
  • 27 Jun 2003 MOR 101 is available for licensing (http://www.morphosys.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top